Experimental monoclonal antibodies block EBV infection
Drug Discovery World
OCTOBER 28, 2022
A panel of investigational monoclonal antibodies (mAbs) targeting different sites of the Epstein-Barr virus (EBV) have been shown to block infection when tested in human cells in a laboratory setting. . There is no licensed vaccine to protect against the virus. . EBV is one of the most common human viruses.
Let's personalize your content